Cornerstone Robotics Ltd. raised an oversubscribed $200 million series D round to accelerate commercialization of its ...

A251, a novel HER2 antibody-drug conjugate (ADC) designed to deliver a potent PI3K/PIKK inhibitor directly to tumor cells.

In a deal worth up to $840 million, Third Arc Bio Inc. is licensing Adagene Inc.’s Safebody technology platform to generate ...

Merck & Co. Inc. is buying Cidara Therapeutics Inc. for $9.2 billion to acquire a late-stage flu candidate and also to ...

The U.S. Environmental Protection Agency has moved to relax reporting requirements for perfluoroalkyl and polyfluoroalkyl substances used in a variety of applications, including medical devices.

ABL Bio Inc. inked a license and research agreement with Eli Lilly and Co. worth up to $2.6 billion to develop multiple ...

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Amsino International, Evonik, Inspira Technologies, Kelyniam Global, MEG Medical Equipment, ...

Biopharma companies focused on infectious disease extended their stock recoveries through the third quarter (Q3), with the BioWorld Infectious Disease Index closing October up 28.98%. The gain marks a ...

A team of five members of the U.S. FDA staff published a review of the use of AI in health care and concluded that while ...

During the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scientists from Plexium Inc. presented the identification of a new class of potent, selective, cereblon ...

The pricier offer by Lundbeck A/S for Avadel Pharmaceuticals plc – which follows last month’s agreement for a takeover by Alkermes plc – had Wall Street buzzing as pundits weighed the odds for each ...

Novartis AG has described peptide-drug conjugates comprising cyclic peptides targeting HER2 (erbB2) covalently linked to a radiolabeled metal chelator through a linker reported to be useful for ...